- 米国企業
- Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc.CTXR
時価総額
$9066.8万
PER
2011年 9月30日 | 2012年 9月30日 | 2013年 9月30日 | 2015年 9月30日 | 2016年 9月30日 | 2018年 9月30日 | 2019年 9月30日 | 2020年 9月30日 | 2021年 9月30日 | 2022年 9月30日 | |
Revenues | - | - | - | - | - | - | - | - | - | - |
Research and development | - | - | - | 2 | 3 | 7 | 9 | 9 | 12 | 18 |
General and administrative | 12,187 | 16,246 | 19,139 | 946,613 | 4 | 6 | 6 | 8 | 10 | 12 |
Stock-based compensation – general and administrative | - | - | - | 486,271 | 732,151 | 779,701 | 715,983 | 803,261 | 1 | 4 |
Total Operating Expenses | 41,137 | 60,755 | 88,873 | 3 | 7 | 14 | 16 | 18 | 24 | 33 |
Operating Loss | -25,637 | -19,618 | -28,118 | -3,229,929 | -7,449,291 | -13,789,143 | -15,598,361 | -17,710,685 | -23,531,894 | -33,316,045 |
Interest income | - | - | - | - | - | - | 52,660 | 68,066 | 261,825 | 251,399 |
Gain on forgiveness of note payable - Paycheck Protection Program and accrued interest | - | - | - | - | - | 450,000 | - | - | 166,557 | - |
Other income | - | - | - | - | - | - | - | 110,207 | 59,917 | - |
Interest expense | - | 3,092 | - | 7,500 | 8,994 | 15,838 | 16,443 | 15,673 | 10,839 | - |
Total Other Income, Net | - | - | - | - | - | - | - | - | - | 251,399 |
Loss before Income Taxes | -26,341 | -22,006 | -31,369 | -2,902,268 | -8,295,698 | -12,536,638 | 16 | -17,548,085 | - | -33,064,646 |
Income tax expense | - | - | - | - | - | - | - | - | - | 576,000 |
Net Loss | -26,341 | -22,006 | -31,369 | -2,902,268 | -8,295,698 | -12,536,638 | -15,562,144 | -17,548,085 | -23,054,434 | -33,640,646 |
Net Loss Applicable to Common Stockholders | - | - | - | - | - | - | - | - | -24,505,310 | -33,640,646 |
Net Loss Per Share Applicable to Common Stockholders - Basic (in Dollars per share) | - | - | - | - | - | - | - | - | - | -0.23 |